Are you ready to invest in your business? A decade ago, software outsourcing was seen as an attractive option for enterprises that wanted to lower operational costs overall when the purpose of the organization was not primarily focused in the IT industry. Nowadays, as the demand for IT resources continues to increase exponentially, offshore software development may be the only acceptable course of action.
Photochemical Reactions of Propenyl and Propynyl Substituted 4-Aminomethyl- and 4-Oxymethyl-2 5H -furanones Heterocycles88 2 The synthetic access to four-membered rings such as cyclobutanes is indeed a challenge using conventional methods - which explains their underrepresentation in Medicinal Chemistry.
Intramolecular photocycloaddition were first performed by irradiation of readily accessible compound 1 with ultraviolet light resulted in the high yield formation of complex scaffold 2 — further steps affording novel diamines 4.
Diamines 4 have been used as a starting point for the enrichment of our compound collection — the rigid, well defined scaffold is used to display a range of substituents through specific vectors.
It clearly shows the power of photochemistry in producing cyclobutanes — for the generation of novel building blocks of distinct three-dimensional shape as new starting points for medicinal chemistry.
He leads drug discovery activities in the context of individual projects and pharmacology platforms. As Director Drug Discovery, Brice provides scientific advices and leadership to portfolio of drug discovery activities projects and pharmacology platforms.
He works with partners from both academia and industry in order to deliver pertinent and optimal biological test cascades as well as safe and efficacious pre-clinical candidate which will be part of the next generation of anti-malarials. Brice has a particular interest in molecules and biological assays that tackle the liver stage of the parasite and more precisely the hypnozoites reservoir in order to find the new drugs that will help eradicate Malaria.
He has broad experience in molecular pharmacology and drug discovery in several disease areas such as Neuroscience, Metabolic Disease and Inflammation, and has successfully led and contributed to teams at all stages of drug discovery.
Brice holds a PhD in Neuroscience and Immunology from the University of Sheffield UK and has published a significant number of scientific papers and patent applications. Since joining AstraZeneca inhe took over the responsibility for a collaborative tool to schedule and visualise outsourced studies with our different partners, he is the Operation Lead for a number of collaborations and a project manager on different exciting projects!
Use of a collaborative tool to simplify the outsourcing of preclinical safety studies: InAstraZeneca entered into a strategic relationship with Charles River Laboratories whereby preclinical safety packages comprising safety pharmacology, toxicology, formulation analysis, in vivo ADME, bioanalysis and pharmacokinetics studies are outsourced.
New processes were put in place to ensure seamless workflows with the aim of accelerating the delivery of new medicines to patients.
Here, we describe in more detail the AstraZeneca preclinical safety outsourcing model and the way in which a chosen collaborative tool, iTraX, has helped to translate the processes in AstraZeneca and Charles River Laboratories into simpler integrated workflows that are efficient and visible across the two companies.
In close collaboration with academic scientists, the CTD develops and subsequently prosecutes innovative drug discovery programmes emerging from academic research. Prior to his current position Andy was a Director of Discovery Medicinal Chemistry at GlaxoSmithKline, covering early lead discovery from screening campaigns, global responsibility for outsource support for lead discovery chemistry and the supply of tool compounds for target validation.
Between and as part of the GlaxoWellcome organisation he led interdisciplinary teams focusing on lead discovery and optimisation incorporating the development of new chemical technologies.
Andy joined the former Glaxo organization as a senior medicinal chemist in following postdoctoral studies in the US, and initially worked on oncology and pain drug discovery programs, leading to one clinical candidate submission.
Andy sits on the RSC Chemistry World editorial board, has been a regular undergraduate lecturer in pharmaceutical medicine at Imperial College, Warwick and Sussex universities, and was the industrial organiser for the RSC Medicinal Chemistry residential summer school between and In he moved to Frankfurt to join Sanofi formerly Aventis and lead global chemistry, natural product and antibody drug conjugate departments in Germany, France and the US and has contributed to the advancement of many projects into clinical development.
Innovation and success rates are major challenges in drug discovery. The result should be value generation: She is leading various projects from hit to lead up to the development of preclinical candidates. Unlocking drug discovery power through collaborative efforts between academia and CRO: Professor Stefan Krauss is a developmental biologist that works on Wnt signaling and discovered the key vertebrate signal Shh.
He has studied aspects of both pathways in different developmental and disease models and is now using chemical biology to deepen the understanding of these pathways and to develop novel therapeutic principles. In addition of being research tools, drugs that attenuate Hh and Wnt signaling have therapeutic implications in various disease areas, including cancer, regenerative medicine and metabolic disorders.
He has worked extensively in early-stage drug discovery across a variety of disease indications including oncology, autoimmune disorders, neurodegeneration and psychiatry. His areas of research interest include the use of chemoinformatic and computational tools within medicinal chemistry, alternative research mechanisms, and the use of new technologies and research collaborations to further the drug discovery process.Advantages and Disadvantages of Outsourcing Outsourcing brings in a lot of flexibility and financial freedom but it also has its pitfalls.
Any company looking to outsource must keep in mind the pros and cons of outsourcing before deciding to take the plunge.
Dr Ulrich Schopfer obtained a Ph.D. in Chemistry from the University of Marburg, Germany. After a postdoc with Prof. R. Noyori at Nagoya University, Japan, he joined Novartis Pharma AG in Basel, Switzerland in Before explaining the potential advantages and disadvantages of offshore outsourcing for various things, I would like to explain few terms like off-shoring, outsourcing and offshore outsourcing.
Off-shoring means taking the work or process to some other country, while on the other side, outsourcing.
Factors to Consider Regarding the Offshore Provider’s Location. In this section, we present a simple and straightforward framework for understanding the advantages and disadvantages of various offshore locations for your outsourced projects and .
EY, in association with Associated Chambers of Commerce and Industry of India (ASSOCHAM), is pleased to present this report, Medical Process Outsourcing in India. Outsourcing can involve signing a contract to have another company perform the function of an entire department or just a single task.
In either case, it means handing over the reins of management and control of that function over to another company.